• Blink

    Can You Guess September's Mystery Condition?

    Download PDF

    Make your diagnosis in the comments, and look for the answer in next month’s Blink.

    September 2017 Blink

     

    Last Month’s Blink

    Congenital Hypertrophy of RPE in Familial Adenomous Polyposis

    Written by Steve G. Lee, MD, LT MC USN, and Joseph W. Schmitz, MD, LCDR MC USN. Photo by Calvin Rogers, CRA. All are at the Naval Medical Center, San Diego.

    August 2017 Blink

    A 17-year-old girl pre­sented with bilateral lesions found on funduscopic examination. She had a history of famil­ial adenomatous polyposis (FAP) and denied having any ocular symptoms. Her BCVA was 20/20 in both eyes. The 5 lesions in her left eye and 1 in her right eye were determined to be congenital hypertrophy of retinal pigment epithelium (CHRPE), a hered­itary thickening of the retinal pigment epithelium (RPE) layer of the retina.

    CHRPE lesions are asymptomatic, flat, and hyperpigmented and vary in color (they may be gray, brown, or black), and they have smooth or scalloped margins that are well-demarcated from the rest of the RPE, which appears normal. CHRPE lesions that are multifocal and bilateral are associated with FAP.1 This is an autosomal dominant disease that presents with ≥ 100 polyps in the colon in the patient’s late 20s or early 30s; it is linked to mutation of the tumor suppressor gene adenomatous polyposis coli. These polyps ultimately develop into colon cancer through the adenoma-carcinoma sequence.

    CHRPE lesions are benign and require no treatment. The patient underwent prophylac­tic total colectomy and remains without ocular symptoms.

    ___________________________

    1 Meyer CH, Gerding H. In: Ryan SJ et al., eds. Retina. 5th ed. London: Saunders; 2013:2209-2213.

    Read your colleagues’ discussion.

    BLINK SUBMISSIONS: Send us your ophthalmic image and its explanation in 150-250 words. E-mail to eyenet@aao.org, fax to 415-561-8575, or mail to EyeNet Magazine, 655 Beach Street, San Francisco, CA 94109. Please note that EyeNet reserves the right to edit Blink submissions.